ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ORGO • US68621F1021

4.05 USD
-0.18 (-4.26%)
At close: Feb 3, 2026
4.05 USD
0 (0%)
After Hours: 2/3/2026, 8:00:02 PM
Fundamental Rating

5

Taking everything into account, ORGO scores 5 out of 10 in our fundamental rating. ORGO was compared to 524 industry peers in the Biotechnology industry. ORGO has only an average score on both its financial health and profitability. ORGO is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ORGO had positive earnings in the past year.
  • ORGO had a negative operating cash flow in the past year.
  • Of the past 5 years ORGO 4 years were profitable.
  • In the past 5 years ORGO always reported a positive cash flow from operatings.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • ORGO has a Return On Assets of -2.63%. This is amongst the best in the industry. ORGO outperforms 87.40% of its industry peers.
  • ORGO has a Return On Equity of -3.47%. This is amongst the best in the industry. ORGO outperforms 89.12% of its industry peers.
  • With an excellent Return On Invested Capital value of 0.16%, ORGO belongs to the best of the industry, outperforming 88.74% of the companies in the same industry.
  • ORGO had an Average Return On Invested Capital over the past 3 years of 3.79%. This is significantly below the industry average of 18.09%.
Industry RankSector Rank
ROA -2.63%
ROE -3.47%
ROIC 0.16%
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • ORGO has a better Operating Margin (0.18%) than 88.74% of its industry peers.
  • In the last couple of years the Operating Margin of ORGO has declined.
  • ORGO has a Gross Margin of 74.49%. This is amongst the best in the industry. ORGO outperforms 83.40% of its industry peers.
  • ORGO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.18%
PM (TTM) N/A
GM 74.49%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ORGO is destroying value.
  • The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
  • ORGO has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ORGO has been reduced compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 3.77 indicates that ORGO is not in any danger for bankruptcy at the moment.
  • ORGO's Altman-Z score of 3.77 is fine compared to the rest of the industry. ORGO outperforms 70.42% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that ORGO is not too dependend on debt financing.
  • ORGO has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 3.77
ROIC/WACC0.02
WACC9.12%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
  • The Current ratio of ORGO (3.32) is worse than 60.11% of its industry peers.
  • ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • ORGO's Quick ratio of 2.88 is on the low side compared to the rest of the industry. ORGO is outperformed by 63.55% of its industry peers.
Industry RankSector Rank
Current Ratio 3.32
Quick Ratio 2.88
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

  • ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.91%.
  • Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
  • ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 2.24%.
  • The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%

3.2 Future

  • Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 29.27% on average per year.
  • ORGO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.70% yearly.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 405.00, ORGO can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, ORGO is valued cheaper than 88.93% of the companies in the same industry.
  • ORGO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.18.
  • Based on the Price/Forward Earnings ratio of 27.38, the valuation of ORGO can be described as expensive.
  • 92.18% of the companies in the same industry are more expensive than ORGO, based on the Price/Forward Earnings ratio.
  • ORGO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.51.
Industry RankSector Rank
PE 405
Fwd PE 27.38
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400

4.2 Price Multiples

  • 93.51% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.82
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • The decent profitability rating of ORGO may justify a higher PE ratio.
  • ORGO's earnings are expected to grow with 29.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ORGO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (2/3/2026, 8:00:02 PM)

After market: 4.05 0 (0%)

4.05

-0.18 (-4.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners54.62%
Inst Owner Change-0.25%
Ins Owners31.34%
Ins Owner Change-0.43%
Market Cap513.99M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (114.07%)
Short Float %19.11%
Short Ratio10.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)0%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)0%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.49%
Valuation
Industry RankSector Rank
PE 405
Fwd PE 27.38
P/S 1.1
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.48
EV/EBITDA 23.82
EPS(TTM)0.01
EY0.25%
EPS(NY)0.15
Fwd EY3.65%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
Industry RankSector Rank
ROA -2.63%
ROE -3.47%
ROCE 0.2%
ROIC 0.16%
ROICexc 0.19%
ROICexgc 0.21%
OM 0.18%
PM (TTM) N/A
GM 74.49%
FCFM N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.11
Cap/Depr 70.73%
Cap/Sales 2.76%
Interest Coverage 0.99
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.32
Quick Ratio 2.88
Altman-Z 3.77
F-Score2
WACC9.12%
ROIC/WACC0.02
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.